Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

VJOncology

Novartis building

Novartis pulls EMA application for expanded Tasigna use

And Boehringer confirms it won't seek approval for faldaprevir as it exits hepatitis C

- PMLiVE

Third time lucky as MannKind’s inhaled insulin is approved

US FDA backs new diabetes treatment Afrezza

- PMLiVE

Comms agencies “intend to do right” by Wikipedia

Ogilvy & Mather, FleishmanHillard, Weber Shandwick and more sign statement on online encyclopaedia

Astellas adds to US comms team

Marty Golden appointed VP, government affairs

- PMLiVE

Biosimilar Lantus leads CHMP opinions

Boehringer and Lilly’s insulin one of six new medicines recommended for EU approval

- PMLiVE

Novartis and NHS launch mobile eye unit in UK

First of its kind unit to offer 250 clinic slots per week across Surrey, Hampshire and Berkshire

- PMLiVE

AbbVie takes PARP inhibitor into third phase III trial

Veliparib under investigation for use in advanced breast cancer

- PMLiVE

Avastin first biologic backed in EU for resistant ovarian cancer

Roche drug recommended in latest round of CHMP opinions

- PMLiVE

Care.Data pilot to be limited to just 100 GP practices

HSCIC admits 'pain' of last 12 months but says health data has transformational potential

- PMLiVE

Astellas picks PhRMA’s Uhlendorf for US public affairs lead

He will leave his role as VP, communications and public affairs at US trade body

- PMLiVE

Langland triumphs at IPA Best of Health Awards

Windsor, UK agency wins Best of Show for Idis campaign

Conversis Medical names Mark Hooper global director

He brings 13 years' experience in pharma services to the role

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links